Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Assets (2016 - 2025)

Historic Assets for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $82.3 million.

  • Protalix BioTherapeutics' Assets rose 3362.57% to $82.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.3 million, marking a year-over-year increase of 3362.57%. This contributed to the annual value of $73.4 million for FY2024, which is 1304.81% down from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Assets of $82.3 million as of Q3 2025, which was up 3362.57% from $78.5 million recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year Assets high stood at $108.2 million for Q2 2021, and its period low was $55.8 million during Q4 2022.
  • In the last 5 years, Protalix BioTherapeutics' Assets had a median value of $78.5 million in 2025 and averaged $78.3 million.
  • Per our database at Business Quant, Protalix BioTherapeutics' Assets plummeted by 4395.77% in 2022 and then surged by 5441.82% in 2023.
  • Over the past 5 years, Protalix BioTherapeutics' Assets (Quarter) stood at $73.7 million in 2021, then fell by 24.27% to $55.8 million in 2022, then skyrocketed by 51.35% to $84.4 million in 2023, then fell by 13.05% to $73.4 million in 2024, then increased by 12.05% to $82.3 million in 2025.
  • Its Assets was $82.3 million in Q3 2025, compared to $78.5 million in Q2 2025 and $73.9 million in Q1 2025.